Paper Details

  1. Home
  2. Paper Details

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.

Author: FarlowMartin R, GauthierSerge, GrossbergGeorge, MengXiangyi, OlinJason T

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 15 cm(2) rivastigmine patch may be an optimal balance between efficacy and safety for the treatment of severe Alzheimer's disease.
Paper Details　
Original Abstract of the Article :
Two sizes of rivastigmine patch (5 cm(2) and 10 cm(2)) are currently approved in the US and Europe, while a 20 cm(2) rivastigmine patch has also been tested. A 15 cm(2) rivastigmine patch may provide an optimal balance between efficacy and safety. Earlier studies have demonstrated the efficacy of ri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007995.2010.513849

データ提供：米国国立医学図書館（NLM）

Higher Doses for Alzheimer's: Evaluating Rivastigmine Patch Efficacy

Alzheimer's disease, a devastating neurodegenerative condition, poses a significant challenge to healthcare professionals and researchers alike. This study investigates the efficacy and safety of a higher dose rivastigmine transdermal patch for treating severe Alzheimer's disease. The researchers explore the potential benefits of this treatment approach, aiming to improve the quality of life for individuals living with this debilitating condition.

A Potential Breakthrough: Higher Dose Rivastigmine for Severe Alzheimer's

This study sheds light on the potential of higher dose rivastigmine transdermal patches for treating severe Alzheimer's disease. While more research is needed to confirm its long-term efficacy and safety, the findings suggest that this approach may offer a promising avenue for improving symptom management and enhancing the quality of life for individuals with severe Alzheimer's.

Managing Alzheimer's: A Continuous Quest for Solutions

This study highlights the ongoing efforts of researchers to develop effective treatments for Alzheimer's disease. The investigation of higher dose rivastigmine transdermal patches represents a crucial step in this ongoing quest. It's a reminder that the pursuit of new and improved treatments for Alzheimer's is a relentless journey, driven by a commitment to improving the lives of those affected by this devastating condition.

Dr.Camel's Conclusion

Just as a camel perseveres through the harsh conditions of the desert, researchers persevere in their quest to find effective treatments for Alzheimer's disease. This study explores a promising new approach, highlighting the potential benefits of higher dose rivastigmine transdermal patches for individuals with severe Alzheimer's. It's a testament to the tireless efforts of researchers to improve the lives of those affected by this debilitating condition.

Date :
  1. Date Completed 2011-02-09
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

20828359

DOI: Digital Object Identifier

10.1185/03007995.2010.513849

Related Literature

Article Analysis
・Effects of rivastigmine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.